ZOMETA^® helps to protect patients like Dieter from the threat of SREs. Efficacy of ZOMETA vs placebo: median time to first SRE^2,6

Efficacy of ZOMETA vs placebo: median time to first SRE^2,6

ZOMETA significantly extended median time to first SRE by more than 5 months
vs placebo (P=.009)²
ZOMETA reduced the risk of SREs by 36% vs placebo (P=.002)²

ZOMETA can delay and reduce SREs in patients like Dieter with prostate cancer and bone metastases^2,6

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA® helps to protect patients like Dieter from the threat of SREs. Efficacy of ZOMETA vs placebo: median time to first SRE2,6

ZOMETA can delay and reduce SREs in patients like Dieter with prostate cancer and bone metastases2,6

ZOMETA^® helps to protect patients like Dieter from the threat of SREs. Efficacy of ZOMETA vs placebo: median time to first SRE^2,6

ZOMETA can delay and reduce SREs in patients like Dieter with prostate cancer and bone metastases^2,6